Targeted therapy for hepatocellular carcinoma: novel agents on the horizon - Wikidata - awgldk - TriplyDB

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

http://www.wikidata.org/entity/Q27002288

about

Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival Recent advances in multidisciplinary management of hepatocellular carcinoma Targeting the insulin-like growth factor pathway in hepatocellular carcinoma GSK-3 as potential target for therapeutic intervention in cancer Advances in targeting signal transduction pathways The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma Genetic alterations in hepatocellular carcinoma: An update Combination treatment including targeted therapy for advanced hepatocellular carcinoma SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma.C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Identification of 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranoside as a Glycine N-Methyltransferase Enhancer by High-Throughput Screening of Natural Products Inhibits Hepatocellular Carcinoma.Network features suggest new hepatocellular carcinoma treatment strategies Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma.Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.The combination of three molecular markers can be a valuable predictive tool for the prognosis of hepatocellular carcinoma patients.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma.Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo Cellular apoptosis susceptibility (CAS) is linked to integrin β1 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC).Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3 The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.

P2860

Q26853543-52F6F8FE-6A7E-461C-8083-9E570FCEB6C7 Q26863748-8B72BE67-3AB2-4A07-999E-348FCACF5F28 Q27006846-010D8598-F4C3-4058-9CC3-6F8E691E927D Q27013811-22BE1868-C773-4560-9D5E-48EC8882B662 Q27686983-0CF7163D-68EE-47B4-84AA-079C52CD9CCB Q28066407-1BABD244-31D4-4AEF-B1BF-4378C6EF7F47 Q28073241-9727190C-12E9-4ED3-935E-43255D314D6D Q28077738-27ADA937-9F41-49EF-8B36-31F72DFF6E41 Q30009010-CD98306F-94C8-42E2-986E-FBCFC5BA26D4 Q33566593-D093FC39-4F0A-4CC8-BEE8-7BE0782FD072 Q33618740-BC633B3B-AAF5-44BE-9C05-407C303858D5 Q33688897-308B03B6-3F89-4322-A32B-09E3362DC28B Q33757127-D559B076-0C6F-4B5A-A58B-2DFCD40708F3 Q33917547-527A1756-F828-401E-9CEB-FC7C79CD6263 Q34104125-7D4879DF-DC18-459C-88F4-12A949D7967F Q34283730-FB5061E5-C411-4C49-82BC-3B8CC8FEA413 Q34307356-9DF182CE-0DD3-4782-AB89-8C7981751F12 Q34525464-8F8FCF0A-FA86-4DAF-8D3C-08C273B67AE1 Q34539069-579FC413-46F0-4F8F-8B0E-32DCE5F82C89 Q34775779-8275D99B-3ADD-4F7B-B010-E7D58FC5797C Q34837850-30072137-7599-4B08-BA16-E07785F3AEFD Q35273600-7A5EF52F-754B-49F9-B43A-E1AB32D717D7 Q35745018-36802AA7-6F50-42FF-9E1D-6C7F776C3DE8 Q35793672-F20FC265-22F4-46AA-A791-92A37C54F981 Q35828564-7D4AAC10-9CD4-429D-B72F-7D5D2D3759EF Q36545292-411B2F00-C029-4982-BE7C-6F884CD7C3DD Q36556350-130876C2-FF50-4C05-8A98-3F127F0B00A5 Q36557155-90E6B11A-3AC2-42DB-B32D-3925DC946D80 Q36562214-B990C6EF-C93B-4A41-B0F9-D9FAFC227AAA Q36799987-00B86703-99E2-404A-8856-BE7C3B075073 Q36862768-E1343C0D-2EAA-4638-B8FF-F279F6213119 Q36950854-EF44D61B-14FF-4CBB-884A-CB63E2089E5B Q37031704-8876077A-E2C5-4EBA-8C13-E343B223BE4F Q37109834-BD7F0834-BDAB-4DEE-9A33-1E3BA8C1DB02 Q37225702-675A32F7-69B3-4FE5-A90A-2F6DF954F220 Q37237164-43505D32-3646-49C5-83B9-B100227DE155 Q37299276-8594EBD1-30E5-4AC4-BE51-5D3A7889E419 Q37324522-D844A76F-2AEB-4315-B1DD-10398E9C7E30 Q37454444-CF12F253-26D3-4D2F-A2BA-6A44EE68B7F8 Q37482829-9A49FAFE-DBFC-436E-9E92-FD8426993F25

P2860

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

http://www.wikidata.org/entity/Q27002288

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@ast

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@en

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@nl

type

label

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@ast

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@en

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@nl

prefLabel

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@ast

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@en

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@nl

P1433

Q27002288-2E2639A4-507E-4BC5-BCAD-BB95964429A3

P1476

Q27002288-211B989F-4F23-4A41-9ECF-7379E445425E

P2093

Q27002288-838513D7-A388-46B0-835F-17E01481A81F

Q27002288-9B3D1CD7-F12D-4BE3-A2C3-169258964F5A

Q27002288-D5591654-F8A1-4C19-A325-E5837232BC9A

Q27002288-E9755E29-2F47-406A-83C6-D906F9887034

P275

Q27002288-2D488BB0-0546-47F1-B34E-2103B0B62F7B

P2860

Q27002288-00EC6F72-46CC-495D-82EC-66727025F7D9

Q27002288-02E65B48-45E2-497C-9FCC-8FBF0969FA40

Q27002288-03D0B5C7-56F6-4C7E-94F9-11B710751F4E

Q27002288-0412EF07-523B-4FEA-894C-FE43C386BF83

Q27002288-04E0669D-A1A8-4D0A-A7F6-46E2EEAF2FE5

Q27002288-064606CD-B370-49E5-A1C3-E51383CD66DA

Q27002288-06C243D1-FB7F-49AF-A328-5375FB583541

Q27002288-08BDE880-A5E3-4570-B01B-DEF8281C5BAD

Q27002288-0A032B00-81F3-462C-9C3E-7F2AFDD8B5DA

Q27002288-0A59A429-69EB-4627-8C0D-73FD92C9B9FB

P304

Q27002288-CA240A58-3740-477F-B2BA-A4DAC3B8D704

P31

Q27002288-297B7C9E-21C6-4462-A98B-7E70F684B6DA

Q27002288-DEEC59D4-DB49-4A38-8576-341D660C18CF

P3181

Q27002288-4D400280-FFA2-488B-BB71-CCE648672AC9

P356

Q27002288-9F7B76D8-691A-47B7-8C08-876CE3B98B76

P407

Q27002288-F50CC4EA-5E09-457A-AD58-B6953B444BAB

P433

Q27002288-5DB9B7F6-ADF4-4CF3-8D77-DF3D7F83C301

P478

Q27002288-7AA0E9E2-CA00-468D-A5ED-7B616AA6EE0A

P50

Q27002288-01F43F51-DA5D-4594-9BD9-A985C764EBDE

Q27002288-166B7125-D2DC-498A-96B2-73B9A6BB948E

P5008

Q27002288-7AC4B962-3FEF-4ECF-9B59-509A24160F81

P577

Q27002288-56DAE330-8DD9-4310-96EB-D114B49DFD7F

Q27002288-A5C9D06A-7B25-42FF-B881-D8ABCB569F65

P5875

Q27002288-C4511EAE-324F-4258-83F0-EB6EE8B2158D

P698

Q27002288-31D9765B-4BA5-4C88-B9BD-B958C9844369

P921

Q27002288-4C5A335C-266F-4478-BDAE-78BFE48ADE61

Q27002288-530BBEE3-EFDD-4094-9AB7-FFFF4BD56BF0

Q27002288-59EEEC5C-70A7-46C8-AF1F-D459DBE032B9

Q27002288-8BF8FEA6-2F75-441A-A867-736B06B09E20

P932

Q27002288-8CDD2EAD-21B7-426D-8C00-35DEBDC18ABD

P3181

P356

P1433

P1476

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

@en

P2093

Antonella Cusimano

http://www.w3.org/2001/XMLSchema#string

Antonina Azzolina

http://www.w3.org/2001/XMLSchema#string

James A McCubrey

http://www.w3.org/2001/XMLSchema#string

Nadia Lampiasi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Direct control of the Forkhead transcription factor AFX by protein kinase B

Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells

Indian hedgehog and beta-catenin signaling: role in the sebaceous lineage of normal and neoplastic mammalian epidermis

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication.

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

P304

236-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1859752

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.466

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Montalto

Melchiorre Cervello

P5008

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223982789

http://www.w3.org/2001/XMLSchema#string

P698

22470194

http://www.w3.org/2001/XMLSchema#string

P921

hepatocellular carcinoma

pharmaceutical preparation

P932

3359882

http://www.w3.org/2001/XMLSchema#string